Abstract
Background The paucity of data describing SARS-CoV-2 in the paediatric population necessitated a broad-arching approach to pandemic planning, with preparations put in place to manage a heterogeneous cohort. We describe a diverse group of SARS-CoV-2 positive paediatric patients treated at a large tertiary/quaternary children’s hospital in the United Kingdom and the adaptive coping strategies required.
Methods All paediatric patients with positive RT-PCR on a respiratory sample and/or serology for SARS-CoV-2 up to 19th May 2020 were included.
Results 57 children met the inclusion criteria. 70% were of non-Caucasian ethnicity with a median age of 9.3 years (IQR 5.16–13.48). Four distinct groups were identified: paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS) (54%), primary respiratory (18%), incidental (7%), and non-specific febrile illnesses with or without extra-pulmonary organ dysfunction (21%). These groups presented in distinct chronological blocks as the pandemic unfolded.
Discussion The diverse range of presentations of SARS-CoV-2 infection in this population exemplified the importance of preparedness for the unknown in the midst of a novel infectious pandemic. Descriptions of paediatric patients during the initial phase of the pandemic from other parts of the globe and extrapolation from adult data did not serve as an accurate representation of paediatric COVID-19 in our centre. An adaptive, multidisciplinary approach was paramount. Expanded laboratory testing and incorporation of technology platforms to facilitate remote collaboration in response to strict infection control precautions were both indispensable. Lessons learned during the preparation process will be essential in planning for a potential second wave of SARS-CoV-2.
Competing Interest Statement
AB received funds for consultative work provided to Gilead Sciences Inc. This consultative work did not impact on the results of the manuscript submitted. No conflicts of interest declared.
Clinical Trial
The project was registered with the local research department (approval #2857)
Funding Statement
No funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The project was registered with the local research department (approval #2857)
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Author Correspondences: NA: Nele.Alders{at}nhs.net NA: Nele.Alders{at}nhs.net JP: Justin.Penner{at}nhs.net KG: Karlie.Grant{at}gosh.nhs.uk CP: Charlotte.Patterson{at}gosh.nhs.uk JH: Jane.Hassell{at}gosh.nhs.uk NM: Nathalie.Macdermott{at}gosh.nhs.uk SP: Sian.Pincott{at}gosh.nhs.uk AB: a.bamford{at}ucl.ac.uk PD: Pascale.DuPre{at}gosh.nhs.uk MJ: Mae.Johnson{at}gosh.nhs.uk KM: Karyn.Moshal{at}gosh.nhs.uk
No funding to declare
Conflicts of Interest: AB received funds for consultative work provided to Gilead Sciences Inc. This consultative work did not impact on the results of the manuscript submitted. No conflicts of interest declared.
Data Availability
Anonymised data was collected and stored in a secure Excel database
